Skip to main content

IO Biotech, Inc.

IOBTDelisted Jun 8, 2026
Industry
Pharmaceutical Preparations
SEC CIK
0001865494

IO Biotech, Inc. was delisted on Jun 8, 2026; its insiders filed their last Form 4 on Jun 6, 2025; 12 institutions reported holding it in 13F filings for Q1 2026, worth $199.0K in total; no superinvestor held it.

Q3 2023 vs. Q2 2023

How the institutions holding IO Biotech, Inc. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of IOBT: Q2 2023 compared with Q3 2023
MeasureQ2 2023Q3 2023Change
Holders1519+4
Shares12.2M29.7M+17.4M (+142.3%)
Value$24.0M$41.7M+$17.7M (+74.1%)

New holders (8)

Institutions that held IO Biotech, Inc. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to IOBT in Q3 2023
InstitutionSharesValue% of portfolio
Armistice Capital, LLC2,148,000$3.03M0.09%
Marshall Wace, LLP2,105,262$2.91M0.01%
Stonepine Capital Management, LLC1,975,308$2.79M0.93%
Alyeska Investment Group, L.P.987,654$1.39M0.01%
Pivotal bioVenture Partners Investment Advisor LLC864,197$1.22M0.49%
Logos Global Management LP493,827$696.3K0.10%
XTX Topco Ltd21,238$29.3K0.01%
Wealth Enhancement Advisory Services, LLC10,100$14.2K0.00%

Sold out (4)

Institutions that held IO Biotech, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.

Institutions that sold out of IOBT in Q3 2023
InstitutionShares, Q2 2023Value, Q2 2023
Aureus Asset Management, LLC43,744$85.5K
Summit Trail Advisors, LLC43,744$85.5K
Citadel Advisors LLC37,690$73.9K
Two Sigma Securities, LLC13,020$25.5K